AlphAIAlphAI — Financial news for AI agents
stocktitan.netSEP 301 min read$VNRX

VolitionRx withholds 608 COO shares for taxes

VolitionRx's COO, Gaetan Michel, disposed of 608 shares of common stock (VNRX) on September 28, 2026, at $0.2529 per share for tax purposes, leaving 12,232 shares owned.

Original reporting
stocktitan.net
Published Sep 30, 2026, 9:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 10:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$VNRX
Neutral
medium confidence
Mentioned
$VNRX
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$VNRXNeutralLow
01

Why it matters

The disclosed sale is small relative to market cap and likely has minimal price impact.

02

Market read

Minor insider sale with limited trading relevance.

03

What to watch

Potential upcoming financing or dilution events not disclosed.

Relevance 4/10Novelty 4/10Timing: filing date 09/30/2026

Background

SEC Form 4 filing discloses insider transactions; VolitionRx is a biotech company.

Company-level read

Ticker impact

$VNRXNeutralMedium confidence
Context

COO Gaetan Michel sold 608 common shares at $0.2529 per share, reducing his stake in VolitionRx Ltd.

Expected impact

likely modest selling pressure as market prices in the insider divestiture

Evidence & confidence

The transaction size is modest and the insider is a senior executive; impact is limited but may signal short‑term weakness.

Market effects

Sector

None significant for the biotech sector.

Regional

No broader regional effect.

Global

Limited to VolitionRx shareholders.

Counterpoint

What could challenge this read

The sale could be a routine tax withholding rather than a negative signal.

Key entities

  • Company
    VolitionRx Ltd

    Biotech firm listed under ticker VNRX.

  • Executive
    Gaetan Michel

    Chief Operating Officer of VolitionRx.

Read at source← All news

Related articles

AUG 26
$VNRXMedAI 8/10

Volition Validates Nu.Q NETs Biomarker In Sepsis; Stock Down

VolitionRx (VNRX) validated its Nu.Q NETs biomarker for sepsis, predicting mortality and kidney therapy needs. Published in Critical Care Medicine, the study found higher levels in septic shock, aiding risk stratification. The $0.34 stock fell 10.37%, amid a $2.8B market opportunity. The company completed a 1-for-20 reverse stock split on April 28, 2026.

rttnews.com2 min
AUG 13
$VNRXLow

VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update

VOLITIONRX LTD (VNRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, August 14 at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, August 13, 2026 /PRNewswire/ -- Volit

SEC EDGAR 8-K3 min
AUG 13
$VNRXMed

VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update

VolitionRx Limited (NYSE American: VNRX) reported Q2 2026 revenue of about $0.4 million, flat versus Q2 2025, and first-half 2026 revenue of $1.4 million, up 112% year over year. Operating expenses fell 32% and operating loss was $4.2 million. The company said it is discussing licensing deals, including a Sysmex collaboration, and expects a $5 million milestone from a Nu.Q Vet feline assay peer review.

prnewswire.com4 min